2023-04-17 来源: drugdu 327
Biosimilar |
Applicant |
Ref. Product |
NMPA Approval |
Launch Date |
HLX01 |
Henlius |
RITUXAN® |
2019-02-22 |
On or before 2019-04-27或之前 |
BAT1406 |
Bio-Thera Solutions |
HUMIRA® |
2019-11-04 |
2020-01-07 |
HS016 |
Zhejiang Hisun |
HUMIRA® |
2019-12-06 |
Launched 已上市 |
QL1101 |
Qilu Pharmaceutical |
AVASTIN® |
2019-12-06 |
Launched 已上市 |
长舒霖® |
Tonghua Dongbao Pharmaceutical |
Lantus® |
2019-12-06 |
2020-02-04 |
安佰诺® |
Hisun Bioray |
Enbrel® |
2019-12-19 |
Launched 已上市 |
益赛普® |
Sunshine Guojian |
Enbrel® |
2019-12-27 |
Launched 已上市 |
锐秀霖® |
Gan & Lee Pharmaceutical |
NovoLog® |
2020-05-12 |
Launched 已上市 |
IBI305 |
Innovent Biologics |
AVASTIN® |
2020-06-17 |
On or before 2020-08-26 或之前 |
HLX02 |
Henlius |
HERCEPTIN® |
2020-08-12 |
2020-08-29 |
强克® |
Celgen Biopharma |
Enbrel® |
2020-08-13 |
Launched 已上市 |
IBI303 |
Innovent Biologics |
HUMIRA® |
2020-09-02 |
On or before 2021-03-29 或之前 |
IBI301 |
Innovent Biologics, co-developed with Eli Lilly |
RITUXAN® |
2020-09-30 |
On or before 2021-03-29 或之前 |
HLX03 |
Henlius |
HUMIRA® |
2020-12-02 |
On or before 2021-03-26 或之前 |
博优诺® |
Boan Biotech |
AVASTIN® |
2021-04-30 |
On or before 2021-06-05 或之前 |
艾瑞妥® |
Jiangsu Hengrui Medicine |
AVASTIN® |
2021-06-22 |
On or before 2021-07-05 或之前 |
CMAB008 |
Mabpharm |
REMICADE® |
2021-07-12 |
Unknown 未知 |
安佰特® |
Zhejiang Hisun |
REMICADE® |
2021-09-24 |
Launched 已上市 |
BAT1706 |
Bio-Thera |
AVASTIN® |
2021-11-17 |
2021-12-10 |
MIL60 |
Betta Pharma |
AVASTIN® |
2021-11-24 |
2022-01-07 |
汉贝泰® |
Henlius |
AVASTIN® |
2021-11-30 |
Launched 已上市 |
TAB008 |
TOT Biopharm |
AVASTIN® |
2021-11-30 |
Unknown 未知 |
泰博维® |
Chia Tai Tianqing Pharmaceutical |
HUMIRA® |
2022-01-18 |
Launched 已上市 |
GB242 |
Genor Biopharma |
REMICADE® |
2022-02-28 |
Unknown 未知 |
UBP1211 |
Junshi Biosciences |
HUMIRA® |
2022-03-02 |
Unknown 未知 |
倍利妥® |
BeiGene |
BLINCYTO® |
2022-05-04 |
Unknown 未知 |
施瑞立® |
Bio-Thera Solutions |
ACTEMRA® (tocilizumab) |
2023-01-16 |
Unknown 未知 |
转载于:https://www.bigmoleculewatch.cn/%e4%b8%ad%e5%9b%bd%e8%8e%b7%e6%89%b9%e7%9a%84%e7%94%9f%e7%89%a9%e7%b1%bb%e4%bc%bc%e8%8d%af-approved-biosimilars-in-china/
责编: editor